Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GLAXF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The GLAXF SEC filings page on Stock Titan provides access to US regulatory documents filed by GSK plc, a global biopharma company. As a foreign private issuer, GSK submits an annual Form 20-F and frequent Form 6-K current reports under the Securities Exchange Act of 1934. These filings, sourced from EDGAR, cover product approvals, clinical trial outcomes, regulatory milestones and detailed transaction notifications for persons discharging managerial responsibilities (PDMRs).
For investors analysing GLAXF, GSK’s 6-K reports are a primary source of information on its vaccines, respiratory and immunology portfolio, and infectious disease pipeline. Recent filings describe European Commission approval of a prefilled syringe presentation for Shingrix, GSK’s recombinant zoster vaccine, and regulatory approvals in Japan for Exdensur (depemokimab) in severe asthma and chronic rhinosinusitis with nasal polyps. Other 6-Ks outline phase III B-Well 1 and B-Well 2 trial results for bepirovirsen, an investigational antisense oligonucleotide for chronic hepatitis B, including definitions of functional cure and key efficacy findings.
GSK’s filings also contain structured PDMR transaction notifications. These tables specify the financial instrument (ordinary shares of 31¼ pence each), ISIN (GB00BN7SWP63), nature of the transaction (such as acquisition of shares via dividend reinvestment or share reward plans), price, volume, date and trading venue (London Stock Exchange). This information allows users to track insider-related share dealings through Form 6-K disclosures.
On Stock Titan, each new GSK 6-K or 20-F is captured and can be paired with AI-powered summaries that explain the main points in plain language. Users can quickly identify filings related to vaccines, respiratory biologics, hepatology candidates or PDMR share activity, and then drill into the original documents for full legal and scientific detail.
GSK plc reported insider acquisitions of American Depositary Shares through automatic dividend reinvestment. On October 14, 2025, ADSs were acquired at $43.9461 per ADS on the New York Stock Exchange, reflecting the reinvestment of dividends paid on October 9, 2025.
Hal Barron acquired 3,186.736 ADSs. James Ford acquired 321.543 ADSs. Shobie Ramakrishnan acquired 387.334 ADSs. Each entry is recorded as a single transaction, with the instrument identified as GSK ADSs (ISIN: US37733W2044).
These transactions are routine dividend reinvestments by directors and senior management and do not reflect an open‑market discretionary purchase program.
GSK plc repurchased 405,500 ordinary shares on 15 October 2025 as part of its existing buyback programme, executed by BNP Paribas SA under a non-discretionary agreement announced on 30 September 2025. The shares were bought at a volume-weighted average price of 1,617.97p, within a price range of 1,608.00p to 1,633.00p, and will be held as treasury shares.
Since 30 September 2025, the company has purchased 3,919,500 ordinary shares. Following this transaction, GSK holds 251,384,344 ordinary shares in treasury and has 4,064,029,485 ordinary shares in issue excluding treasury shares. The total number of voting rights is 4,064,029,485, and the percentage of voting rights attributable to treasury shares is 6.19%.
GSK plc reported routine insider transactions on a Form 6‑K, disclosing that senior executives increased their interests through dividend reinvestment on 2025-10-10. The reinvestments followed dividends paid on 9 October 2025 and were executed in company plans on the London Stock Exchange and, for ADSs, the New York Stock Exchange.
Most entries reflect an increase in notional interest within the Deferred Annual Bonus Plan at £16.4000 per Ordinary Share, including the CEO 3,924 shares, the CFO 1,264 shares, and other executives such as Luke Miels 1,670 shares and Regis Simard 1,134 shares. One ADS transaction shows 417 ADSs at $43.4400 for Shobie Ramakrishnan on the NYSE.
Separately, the CEO acquired 8,786.741 Ordinary Shares at £16.4000 under the Performance Share Plan, which is subject to a 2‑year holding period. Additional small ISA purchases include David Redfern 20 shares at £16.3499 and the Company Secretary 17 shares at £16.3499.
GSK plc reported a share buyback transaction executed through BNP Paribas SA. On 14 October 2025, the company purchased 270,000 ordinary shares at prices between 1,625.50p and 1,649.00p, with a volume‑weighted average price of 1,641.67p. The shares will be held as Treasury shares as part of GSK’s existing buyback programme under a non‑discretionary agreement announced on 30 September 2025.
Since 30 September 2025, GSK has purchased 3,514,000 ordinary shares. After this transaction, GSK holds 250,978,844 shares in treasury and has 4,064,434,985 shares in issue (excluding treasury). The total number of voting rights is 4,064,434,985, and the percentage of voting rights attributable to treasury shares is 6.17%.
Aggregated by venue on 14 October 2025: BATE 25,122 shares (VWAP 1,642.39p), CHIX 77,220 (VWAP 1,641.39p), and XLON 167,658 (VWAP 1,641.69p).
GSK plc reported that China’s National Medical Products Administration approved Shingrix (Recombinant Zoster Vaccine) to prevent shingles in adults aged 18 and over who are at increased risk due to immunodeficiency or immunosuppression. Shingrix is the first and only vaccine approved for this population in China, adding to its existing indication in adults 50 and over.
Shingles places a heavy health burden in China, with approximately six million cases per year. This approval was supported by six clinical trials in adults 18+ following stem cell or kidney transplants, or with blood cancer, solid tumours, or HIV. Shingrix is a non-live, recombinant subunit vaccine combining glycoprotein E with the AS01B adjuvant system. Use should follow official recommendations and local product labels.
GSK plc reported share buybacks under its existing programme. On 13 October 2025, the company purchased 340,000 ordinary shares at a volume‑weighted average price of 1,623.26p (lowest 1,614.50p, highest 1,633.00p). The shares will be held as Treasury shares and the purchases were executed by BNP Paribas SA under a non‑discretionary agreement announced on 30 September 2025.
Since 30 September 2025, GSK has bought 3,244,000 shares. After the latest purchase, GSK holds 250,708,844 shares in treasury and has 4,064,704,985 shares in issue (excluding treasury). The total number of voting rights is 4,064,704,985, and the percentage of voting rights attributable to treasury shares is 6.17%. Detailed venue‑level and trade‑level data were provided for transactions on the London Stock Exchange and Cboe Europe (BATE, CHIX).
GSK plc reported multiple insider acquisitions of equity tied to its October dividend reinvestment. Senior leaders and directors acquired Ordinary Shares on the London Stock Exchange and ADSs on the New York Stock Exchange through the Company’s Share Reward Plan and dividend reinvestment arrangements.
Examples include Emma Walmsley (CEO) acquiring 29 Ordinary Shares at £16.3921 and 105.836 at £16.4016 on 2025-10-09 (XLON). Other UK transactions occurred at £16.3921 or £16.4016 across small volumes by executives and PCAs. On the U.S. line, non-executive directors acquired ADSs at $43.7375 on 2025-10-10 (XNYS), including Charles Bancroft with 340 ADSs and Dr Vishal Sikka with 99 ADSs.
These entries reflect routine dividend reinvestments rather than open‑market discretionary purchases, documenting price and volume for each individual transaction and venue.
GSK plc reported a share buyback transaction conducted via BNP Paribas SA on 10 October 2025. The company purchased 355,000 ordinary shares of 31¼ pence each, paying between 1,623.00p and 1,646.00p per share, with a volume‑weighted average price of 1,635.50p. The shares will be held as Treasury shares under GSK’s existing buyback programme, executed under a non‑discretionary agreement announced on 30 September 2025.
Since 30 September 2025, GSK has bought 2,904,000 ordinary shares. After this purchase, GSK holds 250,368,844 shares in treasury and has 4,065,044,985 ordinary shares in issue (excluding treasury), which is also the total number of voting rights. GSK confirmed the percentage of voting rights attributable to treasury shares is 6.16%. Aggregated by venue on the day: XLON 264,070 shares, CHIX 66,049, and BATE 24,881.
GSK plc filed a report showing several senior leaders acquiring small amounts of GSK ordinary shares through the company’s Share Reward Plan. On 2025-10-09, CEO Emma Walmsley acquired 14 ordinary shares (7 partnership and 7 matching shares) at £16.4083 per share on the London Stock Exchange. CFO Julie Brown, Group General Counsel James Ford, President Corporate Development David Redfern, President Global Supply Chain Regis Simard, President Global Affairs Philip Thomson, and ViiV Healthcare CEO and President Global Health Deborah Waterhouse each acquired 16 shares under the plan at the same price. SVP Global Communications Sally Jackson and SVP & Company Secretary Victoria Whyte each acquired 14 shares on the same terms.
GSK plc reports a share repurchase executed through BNP Paribas SA on
After this transaction GSK will hold 250,013,844 ordinary shares in treasury and will have 4,065,394,695 ordinary shares in issue (excluding treasury), which is also the company's total number of voting rights. The company states that ordinary shares held in treasury represent